MIN-101

From Infogalactic: the planetary knowledge core
Jump to: navigation, search
MIN-101
MIN-101.svg
Systematic (IUPAC) name
2-[[1-[2-(4-Fluorophenyl)-2-oxoethyl]piperidin-4-yl]methyl]-3H-isoindol-1-one
Clinical data
Legal status
  • Investigational
Routes of
administration		 Oral
Identifiers
CAS Number 359625-79-9
PubChem CID: 9799284
ChemSpider 7975049
Chemical data
Formula C22H23F2N2O2
Molecular mass 366.428623 g/mol
  • InChI=1S/C22H23FN2O2/c23-19-7-5-17(6-8-19)21(26)15-24-11-9-16(10-12-24)13-25-14-18-3-1-2-4-20(18)22(25)27/h1-8,16H,9-15H2
  • Key:RNRYULFRLCBRQS-UHFFFAOYSA-N

MIN-101 (former developmental code names CYR-101, MT-210) is a 5-HT2A and σ2 receptor antagonist that is under development by Minerva Neurosciences for the treatment of schizophrenia.[1][2][3][4] One of its metabolites also has some affinity for the H1 receptor.[2] As of August 2015, the drug is in phase II clinical trials.[5]

See also

References

  1. ↑ Lua error in package.lua at line 80: module 'strict' not found.
  2. ↑ 2.0 2.1 Lua error in package.lua at line 80: module 'strict' not found.
  3. ↑ Lua error in package.lua at line 80: module 'strict' not found.
  4. ↑ Lua error in package.lua at line 80: module 'strict' not found.
  5. ↑ MIN 101



<templatestyles src="Asbox/styles.css"></templatestyles>

Stub icon

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.
Retrieved from "https://infogalactic.com/w/index.php?title=MIN-101&oldid=713776942"